← Back to patent-cliff list
Pramipexole Dihydrochloride Hydrate
Tier C — Watch / tradePramipexole Dihydrochloride Hydrate
Boehringer Ingelheim
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DRD2, DRD4, DRD3
Brand：Mirapex-ER, Sifrol, Mirapex, BI-Sifrol, Mirapex-LA, Mirapexin
Indications (approved)：Restless legs syndrome, Parkinson's disease
Regional status
US
Phase II
2001-10-01
EU
Approved
1997-10-13
China
Approved
2005-12-30
Japan
Approved
2003-12-02
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pramipexole Dihydrochloride Hydrate?
Approved indications include: Restless legs syndrome, Parkinson's disease.
When does the Pramipexole Dihydrochloride Hydrate patent expire?
No public expiry year is available for Pramipexole Dihydrochloride Hydrate yet; this page updates once verified.
How do I get a quote for Pramipexole Dihydrochloride Hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27